Presentation ACC 2024 Principal Results from the RELIEVE-HF Trial Presenter: Gregg W. Stone April 06, 2024
Presentation ACC 2024 Mandibular Advancement versus CPAP for BP Reduction in OSA and High Cardiovascular Risk Presenter: Ronald Chi Hang Lee April 06, 2024
Presentation ACC 2024 Main Results From The Step-hfpef Dm Trial Presenter: Mikhail Kosiborod April 06, 2024
Presentation ACC 2024 Empagliflozin after Acute Myocardial Infarction: The EMPACT-MI trial Presenter: Javed Butler April 06, 2024
Presentation ACC 2024 Comparison of an “Inclisiran First” Strategy With Usual Care in Patients With Atherosclerotic Cardiovascular Disease: Results From the VICTORION-INITIATE Randomized Trial Presenter: Michael J. Koren April 06, 2024
Presentation ACC 2024 ApoA-I Event ReducinG in Ischemic Syndromes II (AEGIS-II) Trial Presenter: C. Michael Gibson April 06, 2024
Presentation ACC 2024 Acoramidis May Improve Cardiac Function and Promote Regression in Transthyretin Amyloid Cardiomyopathy: Data From the ATTRibute-CM Cardiac Magnetic Resonance Substudy Presenter: Yousuf Razvi April 06, 2024
News Conference News ACC 2024 Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI Shelley Wood April 06, 2024
News Conference News ACC 2024 Interatrial Shunt Falls Short in Sham-Controlled RELIEVE-HF Michael O'Riordan April 06, 2024
News Conference News ACC 2024 TAVI, SAVR Rates Roughly Equal for Patients Younger Than 65 in New England Yael L. Maxwell April 05, 2024
News Conference News ACC 2024 Faster CAC Progression After Menopause May Warrant Intensified Therapy L.A. McKeown April 04, 2024
News Conference News ACC 2024 Lack of Sleep Ups Hypertension Risk, Especially for Women Yael L. Maxwell April 03, 2024
News Conference News ACC 2024 Heavy Drinking May Contribute to CHD Risk in Young Women L.A. McKeown April 02, 2024
News Conference News ACC 2024 ADHD Meds Linked to Cardiomyopathy in Young Adults Todd Neale April 01, 2024
News Conference News ACC 2024 Even When Nearby, Public AEDs Get Little Use in OHCA L.A. McKeown March 28, 2024
News Conference News ACC 2024 Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It Michael O'Riordan March 27, 2024
News Conference News ACC 2024 Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT Todd Neale March 27, 2024